Suppr超能文献

肠-肝轴、营养与非酒精性脂肪性肝病。

Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.

机构信息

Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville School of Medicine, 40202, Louisville, KY, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, 40202, Louisville, KY, USA.

Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville School of Medicine, 40202, Louisville, KY, USA.

出版信息

Clin Biochem. 2015 Sep;48(13-14):923-30. doi: 10.1016/j.clinbiochem.2015.06.023. Epub 2015 Jul 4.

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases involving hepatic fat accumulation, inflammation with the potential progression to fibrosis and cirrhosis over time. NAFLD is often associated with obesity, insulin resistance, and diabetes. The interactions between the liver and the gut, the so-called "gut-liver axis", play a critical role in NAFLD onset and progression. Compelling evidence links the gut microbiome, intestinal barrier integrity, and NAFLD. The dietary factors may alter the gut microbiota and intestinal barrier function, favoring the occurrence of metabolic endotoxemia and low grade inflammation, thereby contributing to the development of obesity and obesity-associated fatty liver disease. Therapeutic manipulations with prebiotics and probiotics to modulate the gut microbiota and maintain intestinal barrier integrity are potential agents for NAFLD management. This review summarizes the current knowledge regarding the complex interplay between the gut microbiota, intestinal barrier, and dietary factors in NAFLD pathogenesis. The concepts addressed in this review have important clinical implications, although more work needs to be done to understand how dietary factors affect the gut barrier and microbiota, and to comprehend how microbe-derived components may interfere with the host's metabolism contributing to NAFLD development.

摘要

非酒精性脂肪性肝病(NAFLD)代表了一系列涉及肝脂肪积累的疾病,随着时间的推移,这些疾病有可能进展为纤维化和肝硬化。NAFLD 通常与肥胖、胰岛素抵抗和糖尿病有关。肝脏和肠道之间的相互作用,即所谓的“肠道-肝脏轴”,在 NAFLD 的发病和进展中起着关键作用。令人信服的证据将肠道微生物群、肠道屏障完整性和 NAFLD 联系在一起。饮食因素可能会改变肠道微生物群和肠道屏障功能,有利于代谢性内毒素血症和低度炎症的发生,从而导致肥胖和肥胖相关的脂肪肝的发生。用益生元和益生菌来调节肠道微生物群和维持肠道屏障完整性的治疗干预是 NAFLD 管理的潜在手段。这篇综述总结了目前关于肠道微生物群、肠道屏障和饮食因素在 NAFLD 发病机制中的复杂相互作用的知识。尽管还需要做更多的工作来了解饮食因素如何影响肠道屏障和微生物群,以及了解微生物衍生成分如何干扰宿主的代谢从而促进 NAFLD 的发展,但这一综述中提出的概念具有重要的临床意义。

相似文献

1
Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Clin Biochem. 2015 Sep;48(13-14):923-30. doi: 10.1016/j.clinbiochem.2015.06.023. Epub 2015 Jul 4.
4
5
Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Nutrients. 2019 Nov 19;11(11):2837. doi: 10.3390/nu11112837.
6
The Gut Microbiota and Nonalcoholic Fatty Liver Disease.
Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.
7
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH.
Int J Mol Sci. 2020 Aug 13;21(16):5820. doi: 10.3390/ijms21165820.
8
Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
J Microbiol. 2018 Dec;56(12):855-867. doi: 10.1007/s12275-018-8346-2. Epub 2018 Oct 25.

引用本文的文献

1
2
Identification of fecal microbes as potential biomarkers for early diagnosis of fatty liver disease in cattle.
Virulence. 2025 Dec;16(1):2530166. doi: 10.1080/21505594.2025.2530166. Epub 2025 Jul 9.
4
NLRP3 Inflammasome Activation in Liver Disorders: From Molecular Pathways to Therapeutic Strategies.
J Inflamm Res. 2025 Jun 24;18:8277-8294. doi: 10.2147/JIR.S532908. eCollection 2025.
5
Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases.
Front Nutr. 2025 Mar 24;12:1478542. doi: 10.3389/fnut.2025.1478542. eCollection 2025.
6
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD.
Biomedicines. 2025 Feb 6;13(2):393. doi: 10.3390/biomedicines13020393.

本文引用的文献

1
Bacterial cell wall components regulate adipokine secretion from visceral adipocytes.
J Clin Biochem Nutr. 2015 Mar;56(2):149-54. doi: 10.3164/jcbn.14-74. Epub 2015 Jan 8.
3
A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet.
PLoS One. 2014 Dec 11;9(12):e115148. doi: 10.1371/journal.pone.0115148. eCollection 2014.
4
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
J Clin Invest. 2015 Jan;125(1):386-402. doi: 10.1172/JCI76738. Epub 2014 Dec 15.
6
Fructose induced endotoxemia in pediatric nonalcoholic Fatty liver disease.
Int J Hepatol. 2014;2014:560620. doi: 10.1155/2014/560620. Epub 2014 Sep 28.
7
The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota.
Sci Transl Med. 2014 May 21;6(237):237ra66. doi: 10.1126/scitranslmed.3008618.
9
Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis.
Aliment Pharmacol Ther. 2014 Jun;39(11):1276-85. doi: 10.1111/apt.12758. Epub 2014 Apr 16.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验